(Q74082587)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10918405%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

title

High-dose busulfan, melphalan and thiotepa as consolidation for non-inflammatory high-risk breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10918405%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

author

Frederick R. Appelbaum

4

object named as

Appelbaum FR

1 reference

8 November 2019

Gutierrez-Delgado F

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10918405%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

Holmberg LA

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10918405%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

Hooper H

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10918405%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

Livingston RB

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10918405%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

Maziarz RT

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10918405%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

Weiden P

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10918405%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

Rivkin S

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10918405%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

Montgomery P

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10918405%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

Kawahara K

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10918405%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

Bensinger W

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10918405%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

publication date

1 July 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10918405%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

8 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10918405%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10918405%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10918405%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

page(s)

51-59

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10918405%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1702461

8 November 2019

exact match

0 references

cites work

Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702461

7 January 2021

Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702461

7 January 2021

Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702461

7 January 2021

Adjuvant systemic therapy in women with early-stage breast cancer at high risk for relapse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702461

7 January 2021

Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702461

7 January 2021

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702461

7 January 2021

Six-year results of a multimodality treatment strategy for locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702461

7 January 2021

The importance of dose intensity in chemotherapy of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702461

7 January 2021

A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702461

7 January 2021

Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702461

7 January 2021

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702461

7 January 2021

High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702461

7 January 2021

High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702461

7 January 2021

Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702461

7 January 2021

Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analyses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702461

7 January 2021

Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702461

7 January 2021

Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702461

7 January 2021

Sequential treatment including high-dose chemotherapy with peripheral blood stem cell support in patients with high-risk stage II-III breast cancer: outpatient administration in community cancer centers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702461

7 January 2021

Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702461

7 January 2021

High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702461

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702461

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702461

7 January 2021

High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702461

7 January 2021

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702461

7 January 2021

A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702461

7 January 2021

High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702461

7 January 2021

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702461

7 January 2021